Trial Profile
A PROSPECTIVE, NON-INTERVENTIONAL STUDY TO EVALUATE THE CLINICAL EFFECTIVENESS, THE CONSISTENCY OF EVALUATION SCORES, QUALITY OF LIFE, SAFETY AND TOLERABILITY OF TOCILIZUMAB SUBCUTANEOUS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN DAILY CLINICAL PRACTICE
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics
- Sponsors Roche
- 30 Jan 2018 Status changed from active, no longer recruiting to completed.
- 02 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 31 Dec 2015 Planned End Date changed from 1 Mar 2017 to 1 Oct 2018 as reported by ClinicalTrials.gov record.